Zaloglanstat

Overview

Zaloglanstat (ISC-27864; GRC-27864) is a selective, orally active microsomal mPGES-1 inhibitor. Zaloglanstat has an IC 50 of 5 nM for human mPGES-1 without significant inhibitory effect on COX-1/2 ( IC 50 >10 μM). Zaloglanstat blocks the conversion of arachidonic acid metabolite prostaglandin PGH 2 to prostaglandin PGE 2 , thereby inhibiting inflammation-related PGE 2 overproduction and reducing inflammatory responses and pain. Zaloglanstat inhibits IL-1β-induced PGE 2 release in A549 cells and human synovial fibroblasts in vitro . Zaloglanstat inhibits PGE2 release in pig and dog whole blood with IC 50 s of 161 nM and 154 nM, respectively. Zaloglanstat can be used in the study of asthma, osteoarthritis, and neurodegenerative diseases.

Application

Products | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Cytoskeleton | Products > Research Areas > Neurological Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > PGE synthase | Products > Signaling Pathways > Collagen | Products > Signaling Pathways > COX

Product Information

• Catalog No.: HY-139589
• CAS No.: 1513852-12-4
• Molecular Formula: C21H20ClF3N4O2
• Molecular Weight: 452.86
• Purity: 98.50%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution
• Availability: In-stock

Source

Original product source